Weight-loss drugs such as GLP-1 receptor agonists (for example semaglutide and tirzepatide) are producing a wider set of health benefits than just reducing body weight. Because they work on appetite regulation, blood sugar control, and metabolic signalling, the effects extend across several major disease risks.